Benign and malignant kidney tumors were accurately differentiated by the addition of 99mTc-MIBI SPECT/CT to conventional MRI or CT, according to a study published in the Clinical Nuclear Medicine.1
“This noninvasive scan may prevent patients with a potentially benign kidney tumor from having to undergo a surgery,” said Mohamad E. Allaf, MD, MEA, an endowed professor of urology at the Johns Hopkins University School of Medicine in Baltimore, Maryland, in a press release.2
Conventional MRI and CT do not differentiate between benign and malignant kidney tumors. The purpose of this study was to determine if the addition of 99mTc-MIBI SPECT/CT could improve the diagnosis of these conditions.
The study included 48 patients with stage T1 solid renal masses diagnosed by conventional CT and MRI. Prospective evaluation of patients by 99mTc-MIBI SPECT/CT occurred within 8 weeks of the conventional imaging. Two blinded readers diagnosed the kidney mass after conventional imaging and after 99mTc-MIBI SPECT/CT. Surgical pathology was evaluated by blinded pathologists.
The differential diagnostic confidence increased in 29.2% of renal masses. The initial diagnosis by conventional MRI and CT was changed from malignant to benign in 9 cases, which were pathologically confirmed in 7 cases and chromophobe renal cell carcinoma in 2 cases. Five cases were changed from benign to malignant, which were pathologically confirmed.
RELATED: Q&A With Tanya Wildes, MD: Managing Multiple Myeloma in Older Patients
Conventional MRI and CT resulted in an area under the receiver operator curve of 0.60, which improved to 0.85 after 99mTc-MIBI SPECT/CT review (P for difference = .03).
The results of this study suggest that 99mTc-MIBI SPECT/CT use can improve the differentiation between benign and malignant kidney tumors, potentially reducing unnecessary care for some patients.
- Sheikhbahaei S, Jones CS, Porter KK, et al. Defining the added value of 99mTc-MIBI SPECT/CT to conventional cross-sectional imaging in the characterization of enhancing solid renal masses. Clin Nucl Med. 2017;42:e188-e193. doi: 10.1097/RLU.0000000000001534
- Noninvasive imaging test shown accurate in ruling out kidney cancers [news release]. Baltimore, MD: Johns Hopkins Medicine; April 19, 2017. http://www.hopkinsmedicine.org/news/media/releases/ noninvasive_imaging_test_shown_accurate_in_ruling_out_kidney_cancers. Accessed April 20, 2017.